# Communication Valve therapy: Addressing valve dysfunction for long-term heart health.

## Edward Wille\*

Short

Department of Medicine, Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada

## Introduction

Valvular heart disease, characterized by abnormalities in the heart's valves, poses a significant threat to cardiovascular health. However, with advancements in medical technology and surgical techniques, valve therapy has emerged as a crucial approach in addressing valve dysfunction and promoting long-term heart health. This article explores the importance of valve therapy in managing valve dysfunction, its various treatment options, and the impact it has on improving patients' overall cardiac well-being[1].

The heart's valves, including the mitral, aortic, tricuspid, and pulmonary valves, play a critical role in ensuring the unidirectional flow of blood through the chambers of the heart. However, these valves can be affected by conditions such as stenosis (narrowing), regurgitation (leakage), or prolapse (bulging).

Valve dysfunction can lead to symptoms like chest pain, shortness of breath, fatigue, and palpitations. If left untreated, it can lead to serious complications, including heart failure, arrhythmias, and even sudden cardiac death. Valve therapy aims to address these dysfunctions and restore proper valve function to maintain optimal heart health[2].

#### Valve Therapy Options

**Valve repair**: In cases where the valve damage is minimal, valve repair is the preferred approach. It involves preserving the patient's natural valve by correcting structural abnormalities or reinforcing weakened valve components. Valve repair techniques are often employed for mitral valve prolapse and certain aortic valve conditions. Benefits of valve repair include better long-term durability, preservation of the patient's own tissue, and reduced reliance on long-term anticoagulation therapy[3].

**Valve replacement**: When valve damage is severe or repair is not feasible, valve replacement becomes necessary. This procedure involves replacing the malfunctioning valve with either a mechanical valve or a biological valve. Mechanical valves are durable but require lifelong anticoagulation medication. Biological valves, sourced from human or animal tissue, do not require anticoagulation but may have a limited lifespan. Transcatheter aortic valve replacement (TAVR) is a minimally invasive approach to replace aortic valves in highrisk or elderly patients. **Hybrid approaches**: Hybrid approaches combine surgical techniques with transcatheter interventions. These innovative procedures enable less invasive interventions, shorter hospital stays, and faster recovery times. Hybrid valve therapy options are particularly beneficial for patients who are considered high-risk or have complex valve conditions[4].

Valve therapy plays a vital role in improving long-term heart health by addressing valve dysfunction and restoring normal blood flow within the heart. By restoring proper valve function, valve therapy aims to alleviate symptoms, improve exercise tolerance, and enhance overall cardiac function.

Successful valve therapy can help prevent or mitigate complications such as heart failure, arrhythmias, and infective endocarditis. It also contributes to enhancing the patient's quality of life, allowing them to resume their normal activities with reduced symptoms and improved exercise capacity[5].

Moreover, valve therapy requires a multidisciplinary approach involving cardiologists, cardiothoracic surgeons, and an experienced healthcare team. This collaboration ensures comprehensive evaluation, accurate diagnosis, and personalized treatment plans tailored to each patient's specific needs.

#### Conclusion

Valve therapy represents a significant breakthrough in addressing valve dysfunction and promoting long-term heart health. Whether through valve repair, valve replacement, or hybrid approaches, valve therapy offers hope to patients suffering from valvular heart disease, alleviating symptoms, improving cardiac function, and enhancing their overall quality of life.

As technology continues to advance, valve therapy techniques are becoming increasingly precise, minimally invasive, and patient-focused. With ongoing research and innovation, the field of valve therapy holds great promise for further improving outcomes, expanding treatment options, and transforming the lives of individuals with valve dysfunction, ensuring longterm heart health for years to come.

#### References

1. Filsoufi F, Anyanwu AC, Salzberg SP, et al. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg. 2005;80(3):845-50.

\*Correspondence to: Edward wille, Department of Medicine, Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada, E-mail: ed@med.ulaval.ca Received: 30-May-2023, Manuscript No. AACTS-23- 103396; Editor assigned: 02-June-2023, PreQC No. AACTS -23-103396 (PQ); Reviewed: 18- June-2023, QC No. AACTS-23-103396; Revised: 24- June-2023, Manuscript No. AACTS-23- 103396(R); Published: 29- June-2023, DOI: 10.35841/aacts-6.3.150

Citation: Wille E. Valve therapy: Addressing valve dysfunction for long-term heart health. Ann Thorac Cardiovasc Surg 2023;6(3):150

- Butcher JT, Mahler GJ, Hockaday LA. Aortic valve disease and treatment: The need for naturally engineered solutions. Adv Drug Deliv Rev. 2011;63(4-5):242-68.
- Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6):5938-629S.
- 4. Filardo G, Hamilton C, Hamman B, et al. New-onset postoperative atrial fibrillation and long-term survival after aortic valve replacement surgery. Ann Thorac Surg. 2010;90(2):474-9.
- 5. Chiang YP, Chikwe J, Moskowitz AJ, et al. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. Jama. 2014;312(13):1323-9.

Citation: Wille E. Valve therapy: Addressing valve dysfunction for long-term heart health. Ann Thorac Cardiovasc Surg 2023;6(3):150